Viable dopamine neurons in Parkinson's disease express the dopamine transporter (DAT) and release dopamine (DA). We postulated that potent DAT inhibitors, with low affinity for the serotonin transporter (SERT), may elevate endogenously released extracellular dopamine levels to provide therapeutic benefit. The therapeutic potential of eight DAT inhibitors was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated cynomolgus monkeys (Macaca fascicularis), with efficacy correlated with DAT occupancy as determined by positron emission tomography imaging in striatum. Four potent DAT inhibitors, with relatively high norepinephrine transporter, but low SERT affinities, that occupied the DAT improved activity in parkinsonian monkeys, whereas three high-affinity DAT inhibitors with low DAT occupancy did not. 2␤-Carbomethoxy-3␣-(3,4-dichlorophenyl)-7␤-hydroxy-8-methyl-8-azabicyclo[3.2.1.]octane (O-1163) occupied the DAT but had short-lived pharmacological effects. The benztropine analog difluoropine increased general activity, improved posture, reduced body freeze, and produced sleep disturbances at high doses. (1R)-2␤-(1-Propanoyl)-3␣-(4-fluorophenyl)tropane (O-1369) alleviated parkinsonian signs in advanced parkinsonian monkeys, by increasing general activity, improving posture, reducing body freeze, and sedation, but not significantly reducing bradykinesia or increasing locomotor activity. In comparison with the D 2 -D 3 DA receptor agonist quinelorane, O-1369 elicited oral/facial dyskinesias, whereas quinelorane did not improve posture or reduce balance and promoted stereotypy. In conclusion, DAT inhibitors with therapeutic potential combine high DAT affinity in vitro and high DAT occupancy of brain striatum in vivo with enduring daytime effects that do not extend into the nighttime. Advanced parkinsonian monkeys (80% DAT loss) respond more effectively to DAT inhibitors than mild parkinsonian monkeys (46% DAT loss). The therapeutic potential of dopamine transport inhibitors for Parkinson's disease warrants preclinical investigation.
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Parkinson's disease (PD) is the most common of the neurodegenerative movement disorders, with approximately 1% of the population older than 65 years presenting with this progressive disease. Disease symptoms are caused by degeneration of dopamine neurons in the substantia nigra, with significant losses of dopamine and the dopamine transporter (DAT) in the basal ganglia (e.g., Kish et al., 1988; Kaufman and Madras, 1991) . The dopamine precursor L-dopa alone or L-dopa combined with D 2 -D 3 dopamine receptor agonists are drug therapies of choice for treating idiopathic Parkinson's disease. In symptomatic Parkinson's disease, exogenous Ldopa replenishes the endogenous dopamine precursor and augments dopamine production in brain, whereas dopamine agonists activate D 2 -D 3 dopamine receptors directly, obviating the need for dopamine production. Despite their efficacy in early stages of Parkinson's disease, the drugs produce undesirable side effects and waning efficacy with disease progression.
The DAT is another candidate target for antiparkinsonian medications, because DAT blockade produces profound increases in extracellular dopamine in normal striatum (Hurd and Ungerstedt, 1989) . Conceivably, DAT blockers may also function as neuroprotective agents to prevent ongoing degeneration in Parkinson's disease, because the DAT reportedly is a conduit for entry of neurotoxins into dopamine neurons (Uhl, 1998) . Beyond functioning as a carrier for dopamine, DAT may stimulate somatodendritic dopamine release in the substantia nigra (Falkenburger et al., 2001) . Accordingly, DAT inhibitors may augment dopamine levels for receptor activation and protect nigral DA neurons from ongoing degeneration by inhibiting DA and neurotoxin sequestration into DA neurons via the DAT.
In 1961, before the discovery of DAT and other monoamine transporters, methylphenidate (now identified as a DAT inhibitor) reduced rigidity and bradykinesia in a small number of PD subjects (Halliday and Nathan, 1961) . After the discovery of brain DAT, the antiparkinsonian drug benztropine was found to be an effective inhibitor of dopamine transport, leading to speculation that DAT blockade as well as muscarinic cholinergic receptor antagonism contributed to its antiparkinsonian properties (Coyle and Snyder, 1969) . Subsequently, other DAT inhibitors were shown to produce moderate, slight, or no improvements in motor function (Teychenne et al., 1976; Bedard et al., 1977; Park et al., 1981; Delwaide et al., 1983; Goetz et al., 1984; Frackiewicz et al., 2002; Bara-Jimenez et al., 2004) . Clinical interest in DAT inhibitors was heightened with the discovery that methylphenidate potentiated the effects of infused L-dopa, by increasing the percentage of patients' responding and duration of response, while reducing hypotension (Nutt et al., 2004) . The authors concluded that residual DAT is functional in PD and a potential target for symptomatic therapy, particularly if combined with L-dopa. Others revisited the hypothesis that DAT inhibitors have therapeutic potential for PD in preclinical models of PD. High-affinity DAT inhibitors (GBR 12909, BTS 74 398, and brasofensine) increased activity and lowered disability scores in MPTP-treated parkinsonian monkeys or in DA-neuron lesioned rats (Hansard et al., 2002a (Hansard et al., ,b, 2004 Pearce et al., 2002; Lane et al., 2005a,b) .
In the present study, we investigated properties of DAT inhibitors that would presage therapeutic efficacy for treating motor impairment in parkinsonism. We focused on eight novel, chemically diverse analogs of the phenyltropane CFT, or WIN 35,428, which exhibits high affinity for the DAT ( Table 3 ; Madras et al., 1989 Madras et al., , 1996 Madras et al., , 2003 Kaufman and Madras, 1991; Meltzer et al., 1994 Meltzer et al., , 2001 . Selection criteria were initially restricted to high DAT affinity and DAT:SERT selectivity, because SERT inhibitors reportedly attenuate DAT inhibitor-mediated improvements in locomotor activity (Hansard et al., 2002a) . Compounds were tested in the MPTP model of PD in nonhuman primates, initially by screening with an accelerometer. Lead compounds that significantly increased daytime but not night-time activity were then assessed by observer rating of specific behaviors. We also monitored the effects of a lead DAT inhibitor in subjects, with a range of motor impairments (Goulet and Madras, 2000) , to pursue whether a DAT inhibitor would be less ineffective in advanced PD (Bara-Jimenez et al., 2004) . To examine the relationship between therapeutic potential of DAT inhibitors and DAT occupancy or DAT loss, we monitored the DAT in striatum by PET imaging with [
11 C]CFT (Madras et al., 1989 Morris et al., 1996) . High-affinity DAT inhibitors alleviated select parkinsonian symptoms in monkeys, but affinity alone was an insufficient predictor of the therapeutic potential of DAT inhibitors. The results provide guidelines for further assessment of DAT inhibitors as antiparkinsonian medications.
Materials and Methods

Affinities of DAT Inhibitors at DAT, SERT, and Muscarinic Cholinergic Receptors
Tissue Preparation. Brain tissue was harvested from adult male and female cynomolgus monkeys (Macaca fascicularis) euthanized in the course of other studies. Tissue was derived from the brain bank at the New England Primate Research Center (Southborough, MA) and stored at Ϫ80°C. The caudate putamen was dissected from coronal sections of brain tissue (1.4 Ϯ 0.4 g; means Ϯ S.E.M.) and homogenized separately. Membranes were prepared as described previously (Madras et al., 1989) . In brief, the tissue was homogenized in 10 volumes (w/v) of ice-cold Tris-HCl buffer (50 mM, pH 7.4, at 0 -4°C) and centrifuged at 38,700g for 20 min in the cold. The resulting pellet was suspended in 40 volumes of buffer, and the entire wash procedure was repeated twice. The membrane suspension (25 mg, original wet weight of tissue/ml) was diluted to 12 mg/ml in buffer just before assay and dispersed with a Brinkmann Polytron (setting 5; Brinkmann Instruments, Westbury, NY) for 15 s. All experiments were conducted in triplicate, and each experiment was repeated in each of two to four individual tissue preparations. Transport assays were conducted in cell lines expressing the cloned human DAT, NET, or SERT (Madras et al., 2003) .
Competition Assays. The potency of novel drugs for the dopamine, norepinephrine, and serotonin transporters was determined in radioligand binding assays by incubating membranes prepared from individual brain specimens with a fixed concentration of [ 3 H]CFT (dopamine transporter, specific activity ϳ80 Ci/mmol), [ 3 H]nisoxetine (norepinephrine transporter, specific activity ϳ74 Ci/mmol), or [ 3 H]citalopram (serotonin transporter, specific activity ϳ82 Ci/mmol) and a range of concentrations of test compound . Procedures were similar to those described previously . Novel compounds were dissolved in various ratios of ethanol/HCl, at concentrations previously shown to not interfere with binding assays. The assay tubes received, in Tris-HCl buffer (50 mM, pH 7.4, at 0 -4°C; 100 mM NaCl), these constituents at a final assay concentration: test drug or CFT (0.2 ml; 8 -15 concentrations ranging from 1 pM to 100 M), [ 3 H]CFT (0.2 ml; 0.3 nM), membrane preparation (0.2 ml; 4 mg original wet weight of tissue/ml). The 2-h incubation (0 -4°C) was initiated by the addition of membranes and terminated by rapid filtration over Whatman GF/B glass fiber filters (Whatman, Maidstone, UK) presoaked for at least 40 min in 0.1% bovine serum albumin (SigmaAldrich, St. Louis, MO). The filters were washed twice with 5 ml of 50 mM Tris-HCl buffer, incubated overnight at 0 -4°C in scintillation fluor (5 ml; Beckman Ready-Value; Beckman Coulter, Fullerton, CA), and radioactivity was measured by liquid scintillation spectrometry (Beckman 1801). The cpm values were converted to disintegrations per minute following determination of counting efficiency (49 -53%) of each vial by external standardization. Total binding was defined as 3 Hradioligand bound in the presence of ineffective concentrations of unlabeled drug (1 or 10 pM). Nonspecific binding was defined as 3 H-radioligand bound in the presence of an excess drug used to monitor (Madras et al., 2003) .
The norepinephrine transporter in thalamus was assayed by similar methods in a 50 mM Tris-HCl buffer, pH 7.4, which contained 300 mM NaCl . In brief, 0.6 nM [ 3 H]nisoxetine was used to monitor total NET binding. The 16-h incubation at 0 -4°C was initiated by addition of tissue and terminated by rapid filtration over Whatman GF/B glass fiber filters presoaked in 0.3% polyethyleneimine for 1 h. Nonspecific binding was defined as [ 3 H]nisoxetine bound in the presence of an excess (10 M) of desipramine. The serotonin transporter in caudate putamen was assayed using methods similar to those described above. Each tube received in order: test drug or citalopram (0.2 ml; 8 -15 concentrations ranging from 1 pM to 100 M), [
3 H]citalopram (0.2 ml; 1 nM), membrane 
Animals
Observations were made on a total of 13 cynomolgus monkeys (two females, 11 males, ages 2-10 years) housed singly at the New En- 
Videotape Rating of Behaviors
Animals (M. fascicularis) were placed in a large filming cage (85 ϫ 79 ϫ 88 cm) with food and other enrichment items, with full access to water. Filming was done in the animal housing room to maintain a familiar home environment. A video camera, focused on one Plexiglas cage side panel, was activated. Before drug treatment, baseline behavior for each subject was filmed for 7 h. Vehicle (saline) was injected immediately after the close of the first half-hour session. Drugs were administered via intramuscular injection, and filming continued for 6 h. Videotapes were rated by an observer blinded to the drug treatments. Several monkeys had a prior history of acute jpet.aspetjournals.org drug treatments but had not been treated with any drugs for at least 2 months. Others were placed specifically in this study with no prior exposure to drugs, with the exception of MPTP.
Monkeys were fitted with a jacket containing an inaccessible back pocket, into which an accelerometer was placed. For videotaping, animals were transferred via a transfer box to a large cage fitted with a Plexiglas front window to facilitate videotaping. Taping was conducted from 9:00 AM to obtain baseline activity levels and was continued for as long as 6 h after the last dose of drug. In the videotaping cage, animals had full access to food and water.
MPTP Lesion
Animals were anesthetized with ketamine, an indwelling venous catheter was implanted, and parkinsonism was induced by two or three injections of MPTP (0.6 mg/kg MPTP⅐HCl i.v., dissolved in saline) within 45 days. Animals were generally able to maintain feeding and drinking behavior. Some animals displayed improvement after the initial decline. The behaviors and activities of the subjects were monitored for 5 to 14 days before initiation of each drug study, and parkinsonian symptoms remained stable before the drug experiments (Goulet and Madras, 2000) . Mild and advanced parkinsonism were designated empirically and reflected scores on the parkinsonian rating scale and DAT imaging.
Drug Testing
Drug treatments were administered in random order. To determine maximal effective doses of the compounds, monkeys received a cumulative dose (spaced 0.5 h apart) of test compound to determine a dose-response function via the accelerometer. After an interval of 2 to 4 weeks, monkeys received single i.m. injections of test compound. At the end of each treatment period, all monkeys were given a minimum 14-day injection-free period. Baseline activity values were determined both by measuring activity in the absence of drug and by monitoring activity after an i.m. injection of saline. All drugs were dissolved in vehicle (minimal concentrations of ethanol and/or HCl in sterile saline), and vehicle was tested to determine whether the composition of the vehicle or injection per se influenced activity. To determine dose-response effects, difluoropine was dissolved in vehicle and administered at noon daily in single doses (0.1-3.0 mg/kg) i.m. after a vehicle injection, and O-1369 (0.1-3 mg/kg) and quinelorane (0.05 mg/kg) were administered similarly.
Behavioral Analyses: Rating Scale
For behavioral analysis, videotapes were scored independently by an observer blinded to the treatment. Inter-rater reliability generally exceeded 90% after a period of training. The rating scale measured the following behaviors: general activity, locomotor activity, bradykinesia, rigidity, posture, imbalance, tremor frequency, body freeze, feeding ability, oral/facial dyskinesia, limb dyskinesia, trunk dyskinesia, stereotypy, sedation, self-grooming, social interaction, penile erection, vomiting, head scanning, and tail rigidity ( Table 1) . The ratings enabled estimates of parkinsonism signs as well as dyskinesias and other symptoms of dopaminergic drug treatment (stereotypy, self-grooming, penile erection, vomiting, head scanning, and tail rigidity). The ethogram scale and analysis were devised after repeated observation of individual behavioral motifs of normal and MPTP-treated monkeys on videotape (Goulet and Madras, 2000) . The intensity and frequency of occurrence of individual behaviors were assessed, and, based on analysis of the behaviors observed, we focused on seven behaviors that were significantly affected by MPTP: general activity, locomotor activity, bradykinesia, body freeze, rigidity, postural abnormalities, and sedation. Nonetheless, all other behaviors reflecting potential therapeutic and side effects were also rated. Oral/facial dyskinesia, stereotypy and penile erection following drug exposure are presented (Table 1) . Other behaviors did not show differences in baseline or following drug treatments. Tapes were divided into 30-min segments. Data consist of observational ratings in 2-min blocks for 6 h after drug administration, with each segment scored in 2-min observation periods every 5 min (5, 10, 15, 20, and 25 min) into the session and the average of each segment was used for analysis. Each 30-min time period after drug administration generated five observational scores. Baseline behavior was rated either with no intervention or after saline injections, with an average of 70 baseline observations in each animal before drug administration. Each behavioral motif was given a score of Ϫ1, 0, 1, or 2. Behavioral changes assumed to derive from excess dopaminergic activity (e.g., dyskinesias) were assigned scores of Ϫ1. Statistical analysis of the data were based on average scores for each 30-min observation period, during treatment, and compared with baseline levels of activity, monitored for four or more sequential days before drug treatment.
Computerized Monitoring of Movement
Motor activity was assessed with an omnidirectional accelerometer (Actiwatch aw4-64K; Mini-Mitter, Sunriver, OR). The animals were sedated with 10 mg/kg ketamine and were fitted to a jacket according to their weight (Lomir, Montreal, QC, Canada). To increase comfort, the jacket was sleeveless and fabricated with an inaccessible pocket (3 ϫ 3 inches) in the lower back. The accelerometer unit was placed in a hard case and inserted in the jacket pocket after a period of 2 to 4 weeks to accommodate to the jacket. The accelerometer was set to record activity continuously every minute for 30-to 45-day periods. Baseline levels of activity were generated for at least 5 days before drug administration, and then activity was compared in predrug and postdrug sessions. The data were analyzed with the software Rhythmwatch (Mini-Mitter), and activity counts were divided into segments as designated and compared with baseline levels of activity.
PET Imaging of the DAT
PET imaging of the DAT in caudate putamen was used for two purposes: to measure the extent of MPTP-induced dopamine neuron degeneration and to determine DAT occupancy by candidate therapeutics. DAT was quantified with the selective DAT probe [
11 C]CFT (Kaufman and Madras, 1991; Morris et al., 1996; Madras et al., 2001) . PET imaging was conducted with monkeys initially anesthetized with ketamine/xylazine (15.0/1.5 mg/kg) and then maintained under general anesthesia with halothane and positioned prone on the imaging bed of a PC 4096 PET camera (GE/Skanditron AB, Uppsala, Sweden). A stereotactic head-holder was used for head immobilization. CFT was demethylated in the C-2 position, and [ 11 C]methyl was inserted by the methyl iodide reaction. After stabilization in the PET camera, ϳ10 mCi of [ 11 C]CFT (specific activity Ͼ1500 mCi/mol) was injected through the venous catheter, and sequential images were acquired in 15-s time frames for the first 2 min and in 1-min frames for 58 min. At the conclusion of each imaging study, the emission and transmission images were reconstructed using a conventional filtered back-projection algorithm to an in-plane resolution of 6-mm full-width half-maximum. All projection data were corrected for nonuniformity of detector response, dead time, random coincidences, and scattered radiation. A sum image was generated by adding all the frames from frame 10 to the end of the study. Regions of interest were drawn on the summed image in the coronal projection as follows; one 4-pixel region was drawn on each caudate putamen on the slice of maximum intensity. For cerebellum, three regions were drawn on cerebellar slices. Time-activity data were produced using the regions of interest on all time frames of the PET data. The same set of regions of interest was used to analyze each scan for an individual subject on the same day. When necessary, new regions were drawn to compensate for repositioning. Binding potential was calculated by published methods . 
Drugs
Data Analysis
One-way analysis of variance, nonparametric analysis with Dunnett's comparison with baseline controls was performed, using GraphPad Instat for Windows (GraphPad Software Inc.). Other statistical tests are mentioned in text. Graphs were prepared by the GraphPad Prism 4.
Results
Receptor Binding Profile. Of a wide range of phenyltropane analogs designed collaboratively over the past decade by the author (Fig. 1) , we investigated seven high-affinity DAT inhibitors with low affinity for the SERT and one prodrug (O-2240). With the exception of O-2240, all of the compounds inhibited [
3 H]CFT binding with affinities less than 40 nM, the majority having less than 10 nM affinities ( Table  2 ). The rank order of potencies of the compounds for inhibit- (Table 2) . A sim- O-1231, and O-1973) generally were less potent at the NET, compared with the DAT. The main focus of the study was two lead compounds, difluoropine, a benztropine analog, and O-1369, an analog of WIN 35,428 (CFT) ( Fig. 1; Table 2 ). Of eight possible isomers previously characterized, difluoropine emerged as the most potent within a series of benztropine analogs (Meltzer et al., 1994) , and it was 15 times more potent than its progenitor benztropine (Table 2 ). In further distinction to benztropine, difluoropine displayed low affinity for the muscarinic cholinergic receptor (Tables 2 and 3) . O-1369, which lacks a hydrolyzable ester link in the C-2 position and is considered to be more metabolically stable than its progenitor compound, displayed high affinity (K i ϭ 15.1 nM) in blocking DAT transport function ( Fig. 1 ; Tables 2  and 3 ). In a receptor screening array, 10 M difluoropine displayed some activity at -opiate receptors and inhibited nicotinic cholinergic receptor activity at 1 M (Table 3) . O-1369 displayed low affinity (Ͼ10 M) for a wide range of receptors, but it seemed to enhance 5-hydroxytryptamine 1Db receptor activity at this concentration, possibly indicative of agonist activity (Table 3 ). The potencies of clinically relevant DAT inhibitors (mazindol, methylphenidate, nomifensine, and bupropion) are shown in Table 2 , for comparative purposes.
Pilot Screening of DAT Inhibitors. Pilot screening of compounds was conducted using an accelerometer in parkinsonian monkeys with varying activity levels, measured before and after drug administration. Activity was monitored 1 to 2 weeks preinjection and 3 to 6 days postinjection to monitor onset and duration of effect. Using a range of doses (0.01-3 mg/kg i.m.), we assessed a novel group of DAT inhibitors (O-1014, O-1231, and O-1973) , which contain no amine nitrogen in their structure (Madras et al., , 2003 . The three nonamines ( Fig. 1; Table 2 ) produced little or no increases in activity of parkinsonian monkeys on the day of, or for 6 days after, administration compared with baseline levels of activity (data not shown).
O-1163, a 7-hydroxylated phenyltropane analog with a hydrolyzable ester in the 2␤-position, was selected on the basis of high DAT affinity and DAT:SERT selectivity and for comparison with O-2099, the 2␤-propionyl analog that is not hydrolyzable in this position. O-2099 was compared with O-2240, a putative prodrug of O-2099 that, by virtue of its hydrolyzable carbon chain to mask the 7-hydroxyl group of O-2099, conceivably would provide extended DAT blockade and therapeutic benefit. O-1163 was administered in single doses (0.1-6 mg/kg i.m.) on separate days. O-1163 increased activity during the first hour after administration (Fig. 2) , an effect that dissipated at 90 min and did not reoccur during the day or subsequent days.
In contrast, O-2099 (Fig. 3, A and B) , O-2240 (Fig. 4) , difluoropine (Fig. 5) , and O-1369 (Fig. 6 ) increased activity levels of parkinsonian monkeys for Ͼ1 h, as measured by an accelerometer. Amplified scrutiny was given to the lead compounds difluoropine and O-1369 (see below). O-2099, a nonhydrolyzable analog of O-1163 (Fig. 1) , was tested only at 0.1 mg/kg, after seizures and death of one normal monkey after a 3-mg/kg dose in a dose-response study. O-2099 significantly increased daytime activity levels of parkinsonian monkeys (n ϭ 3) to 144% of baseline activity (p Ͻ 0.02; n ϭ 3) compared with four control days before drug exposure. In one animal, activity persisted at higher levels (125% of baseline; p Ͻ 0.01) on the following day (Fig. 3A) . Although it is possible that other factors may have promoted activity in this subject, the high affinity of O-2099 suggests that the compound may persist and promote activity in subject-specific manner. O-2099 did not significantly increase activity during the night time. Based on this positive result, we conducted a more extensive survey of the behavioral effects of O-2099 by filming and rating behaviors for 6 h after drug administration, using a rating scale reported previously to effectively distinguish MPTP-induced parkinsonism in monkeys from normal animals (Table 1 ) and drug-induced improvements (Goulet and Madras, 2000) . Improvements in general activity and sedation, but not locomotor activity, were prominent 4 h after injection (Fig. 3B) . Bradykinesia, balance, rigidity, body freeze, and other parameters did not differ significantly from baseline values (data not shown). Oral/facial dyskinesias increased (not statistically significant) and were observable at earlier time points than motor improvements (data not shown). O-2099 did not significantly increase activity during the night time. Based on high DAT occupancy levels at 0.1 mg/kg (Table 4) and high potency at 0.1 mg/kg, O-2099 is the most potent compound we tested.
The prodrug of O-2099, O-2240, conceivably could provide a more durable response than O-2099 (Fig. 1) . O-2240 was administered twice, with the second dose given 2 days later to determine whether this prodrug produced cumulative effects in the course of being metabolized to its active form. After administration at 8:30 AM and monitored by accelerometry, O-2240 did not change activity during the first 3.5 h, but it increased activity levels in the afternoon (12:00 PM-6:00 PM) (Fig. 4A, top) . After the second dose on day 3, O-2240 again increased activity, but the increase did not Fig. 2 . Pilot study of activity of parkinsonian cynomolgus monkeys (accelerometer) before and after treatment with the candidate DAT inhibitor O-1163 ( Fig. 1; Table 2 ). Parkinsonian monkeys (n ϭ 3) were monitored 24 h continuously at 1-min intervals with an accelerometer. Dose-response effect of O-1163 from 8:30 to 9:30 AM, the only time period in which O-1163 was active. persist on subsequent days during the same time period (Fig.  4A, top) . During normal sleep hours, O-2240 increased activity from 6:00 PM to 12:00 AM (Fig. 4, B and C) , with the most robust increase detected from 12:00 AM to 6:00 AM on day 2, after the second dose (Fig. 4C, bottom) . Based on the modest effects of O-2099 on daytime activity, dose limitations, and heightened activity elicited by O-2240 during the dark cycle, we focused on other high-affinity DAT inhibitors, difluoropine and O-1369.
Effects of Difluoropine on Activity and Behaviors.
The benztropine analog difluoropine was selected because of high affinity and low muscarinic cholinergic receptor affinity ( Fig. 1; Table 2 ). Conceivably, these in vitro properties would clarify whether the antiparkinsonian effects of benztropine (difluoropine progenitor) require muscarinic cholinergic receptor blockade (Coyle and Snyder, 1969) . Difluoropine effects on motor function and other behaviors were monitored in normal (n ϭ 4) and in MPTP-treated cynomolgus monkeys (n ϭ 5), as illustrated in Fig. 5 (left, normal monkeys; right, MPTP-treated monkeys). Subjects were treated with various Baseline behavior was filmed and scored for 5 days, and drug was administered on day 6. Data are scores recorded for 6 h after drug treatment (means Ϯ S.E.M.; n ϭ 4) of parkinsonian monkeys ‫,ء(‬ p Ͻ 0.05). 
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doses of difluoropine (0.1-3.0 mg/kg), and activity was rated by an observer (Table 1 ) and monitored by an accelerometer. Difluoropine was administered cumulatively at 30-min intervals and after the last dose (3.0 mg/kg), observations were continued at 30-min intervals (f1-f7) for an additional 3.5 h. Each data point is based on five observations made during 30-min intervals (means Ϯ S.E.M.). All values were compared with baseline control activities (Ctrl), monitored for 4 to 8 days before injection of the test compound (means Ϯ S.E.M.). Saline vehicle (veh) was administered i.m. 30 min before the first dose of difluoropine to determine injection effects, but no statistically significant injection effects were detected compared with baseline levels. In normal animals, cumulative doses of difluoropine (0.1-3 mg/kg) affected behaviors differently than in parkinsonian monkeys. Difluoropine reduced locomotor activity (not statistically significantly) in accord with the locomotor-reducing effects of cocaine, a DAT inhibitor, in monkeys (Saka et al., 2004) . Difluoropine also increased rigidity, but, with high interindividual variability, changes were not statistically significant (data not shown). In MPTP-treated parkinsonian monkeys, difluoropine dose-dependently increased general activity (Fig. 5A , top right; ‫,ء‬ p Ͻ 0.05), reduced severe body freeze (Fig. 5A , right, third from top; ‫,ءء‬ p Ͻ 0.004), and improved posture (Fig. 5A , right, fourth from top). During the 2 h of maximal effectiveness (f4 -f7 interval or 3-3.5 h after the last dose), difluoropine significantly improved general activity, posture, and body freeze (Fig. 5A , bottom right; ‫,ء‬ p Ͻ 0.05). This composite behavioral score was limited to these parameters, because in congruence with other DAT inhibitors (see below), these consistently achieved statistical significance. This composite score is also illustrated because it corresponded temporally to improved activity as monitored by the accelerometer. Accordingly, the latter device may serve as a rapid screening tool for antiparkinsonian drug effects of DAT inhibitors. Difluoropine increased oral/facial dyskinesias (not significant) and head scanning ( Fig. 5B, left ; ‫,ء‬ p Ͻ 0.05, ‫,ءء‬ p Ͻ 0.01). At the highest doses tested (3-6 mg/kg), difluoropine promoted sleep fragmentation ‫,ء(‬ p Ͻ 0.05) on the night after early morning administration (Fig. 5B, right) . Sleep fragmentation, an index of restlessness, is calculated as a percentage of minutes spent moving compared with immobility, during the dark cycle (lights out). Based on low muscarinic cholinergic receptor affinity, difluoropine improved motor function independently of muscarinic cholinergic receptor antagonism.
oropine to determine injection effects. There were no statistically significant injection effects compared with control values. Each data point is based on five observations made during 30-min intervals (means Ϯ S.E.M.) (Dunnett's multiple comparison with control; ‫,ء‬ p Ͻ 0.05). Bottom right, composite score of those behaviors that significantly improved in parkinsonian monkeys as a function of dose and time (Dunnett's multiple comparison with control; ‫,ء‬ p Ͻ 0.05). B, side effect profile of difluoropine on various behaviors and sleep fragmentation. Difluoropine was administered i.m. cumulatively at 30-min intervals to MPTP-treated parkinsonian monkeys (n ϭ 5) as described above. Left, effects of difluoropine on oral/facial dyskinesia (O/F) and head scanning were quantified according to the rating scale described in Table 1 . Ctrl data are based on observations with no i.m. injection and represent baseline levels of activity (means Ϯ S.E.M.). Saline veh was administered i.m. 30 min before the first dose of difluoropine to determine injection effects, but these effects were not significant. Right, sleep fragmentation in MPTP-treated monkeys produced by 3 to 6 mg/kg difluoropine. Results are means Ϯ S.E.M.; n ϭ 4 ‫,ء(‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01). Table 1 ). Difluoropine was administered cumulatively (0.1-3.0 mg/kg) at 30-min intervals and after the last dose (3.0 mg/kg), observations were continued at 30-min intervals (f1-f7) for an additional 3.5 h. Difluoropine effects on normal cynomolgus monkeys (left) and in parkinsonian monkeys (right). Ctrl data are baseline levels of activity with no i.m. injections, monitored for 4 to 8 days (means Ϯ S.E.M.). Veh was administered i.m. 30 min before the first dose of diflu- (Fig. 5A, top left) , we postulated that the response of parkinsonian monkeys to DAT inhibitors could reflect the extent of motor impairment before drug exposure. We vigorously tested this postulate with a lead DAT inhibitor, O-1369, in subjects with a range of baseline levels of activity. A cohort of eight MPTP-treated monkeys was divided into two groups, mild (n ϭ 4) and advanced parkinsonism (n ϭ 4), based on observational (Fig. 6, A and B) and PET imaging data (Fig. 6C) . The individual parkinsonian scores of seven behaviors distinguished the two groups of mild and advanced, based on general activity ‫,ءءء(‬ p Ͻ 0.007), locomotor activity ‫,ءءء(‬ p Ͻ 0.005), bradykinesia ‫,ءءء(‬ p Ͻ 0.008), rigidity ‫,ءءء(‬ p Ͻ 0.006), posture (p Ͻ 0.007), body freeze (p Ͻ 0.006), and sedation ‫,ء(‬ p Ͻ 0.04) (Fig. 6A, top left) . One group displayed composite scores exceeding 7.0 (range 7.43-10.56, of a maximal possible score of 12) and was designated as "advanced parkinsonism." The other group, with scores of 4 or less (range 0.56 -4.01), was designated "mild parkinsonism" (Fig. 6B) . The averaged composite score for the mild cohort differed significantly from the advanced cohort (Fig.   6B , top right; p Ͻ 0.005). To compare these composite scores with dopamine neuron viability, we conducted PET imaging in each of the subjects. DAT binding potential, detected with the PET ligand [
11 C]CFT, correlated significantly (r 2 ϭ 0.71; p Ͻ 0.01) with the composite parkinsonism score (Fig. 6C,  bottom) . Before MPTP administration, baseline DAT binding potential in the mild and advanced groups did not differ: 2.32 Ϯ 0.33 (mild group: means Ϯ S.E.M.; n ϭ 4) and 2.38 Ϯ 0.06 (advanced group: means Ϯ S.E.M.; n ϭ 4). After MPTP administration, DAT binding potential declined to 1.25 Ϯ 0.26 in the mild group (means Ϯ S.E.M.; n ϭ 4) and to 0.45 Ϯ 0.04 in the advanced group (means Ϯ S.E.M.; n ϭ 4) (p Ͻ 0.02), equivalent to a loss of 52 and 80% of DAT. The two groups differed from their normal baseline DAT binding potential (mild: p Ͻ 0.04; advanced: p Ͻ 0.0001). Intriguingly, the 30% lower DAT binding potential of advanced parkinsonian monkeys was associated with a 3-fold increase in parkinsonism scale.
O-1369, a 3␣-fluorophenyltropane analog of CFT, or WIN 35,428, was selected for scrutiny on the basis of two considerations: first, the 3␣-boat-conformer is considerably less potent at the SERT and, accordingly, l more DAT:SERT-selec- jpet.aspetjournals.org tive than its 3␤-diastereomer; and second, the 2␤-propionyl moiety that replaced the 2␤-carbomethoxy group is less likely to undergo enzymatic hydrolysis. The behavioral effects and sleep patterns of the potent DAT inhibitor O-1369 were investigated in this larger cohort of parkinsonian monkeys (n ϭ 8), with varying degrees of MPTP-induced parkinsonism. Baseline activity was acquired for five consecutive days, then dose-response effects of O-1369 (0.1, 0.3, 1.0, and 3.0 mg/kg i.m., given between 8:00 and 8:30 AM) on activity of four advanced parkinsonian monkeys were monitored by an accelerometer (Fig. 7A, top, inset) . Activity was measured in 1-min units and averaged for 30-min blocks. Results are expressed as percentage of increase over baseline activity levels, for 4.5 h after administration. Subsequently, the effects of a fixed dose of O-1369 (3.0 mg/kg i.m.) on activity of eight subjects with a range of parkinsonian symptoms (mild and advanced parkinsonism) during peak drug response were monitored by an accelerometer (Fig. 7A, top) . Data expressed as average activity counts, computed each minute starting at 30 min after drug treatment, were averaged in 30-min blocks, for 3.5 h. O-1369 increased activity in advanced parkinsonian monkeys with low activity levels (1, 3, and 4, but not 2), and in one higher activity animal (6) (means Ϯ S.E.M.; ‫,ء‬ p Ͻ 0.03, ‫,ءء‬ p Ͻ 0.01; Fig. 7A, top) . We subsequently measured the effects of O-1369 (3 mg/kg i.m.) on behavior in the same cohort of eight monkeys displaying mild parkinsonism (Fig. 7B, middle) or advanced parkinsonism (Fig. 7C) . In mild parkinsonism (Fig. 7B, middle) , none of the behaviors improved significantly with O-1369 (means Ϯ S.E.M.; n ϭ 4). (black bars designating posture, body freeze, and sedation were not visible because behavior was restored to zero for these parameters.) In advanced parkinsonism (Fig. 7C, bottom) , O-1369 significantly improved selective, but not all behaviors compared with baseline activity (means Ϯ S.E.M.; n ϭ 4): general activity ‫,ءء(‬ p Ͻ 0.016), posture ‫,ء(‬ p Ͻ 0.03), body freeze ‫,ء(‬ p Ͻ 0.03), and sedation ‫,ء(‬ p Ͻ 0.03) improved, but locomotor activity (N.S.), bradykinesia (N.S.), and rigidity (N.S.) did not (n ϭ 4). The behavioral effects of O-1369 in advanced parkinsonism are shown as a function of time (Fig. 8) . The most robust improvements, general activity, posture, body freeze, and sedation, improved within 60 min ‫,ء(‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01) and were measurable for 3 h or longer (Fig. 8) . Locomotor activity, bradykinesia, and rigidity displayed slight, time-dependent improvements, but changes were not statistically significant (data not shown). In five parkinsonian monkeys with various degrees of impairment, O-1369 increased sleep fragmentation (p Ͻ 0.01), at double the dose (6 mg/kg) found to be behaviorally effective (3 mg/kg; Fig. 9 ), but it did not significantly affect sleep latency or efficiency. Behavioral Effects of a D 2 -D 3 Agonist: Quinelorane. To compare the behavioral effects of DAT inhibitors with a D 2 -D 3 dopamine receptor agonist, animals were treated with quinelorane, a D 2 -D 3 DA receptor agonist effective in alleviating MPTP-induced parkinsonian symptoms (Goulet and Madras, 2000) and with the same pharmacological targets as clinically active D 2 -D 3 dopamine receptor agonists. Behavior in eight monkeys (not all were identical to the eight monkeys used for O-1369 study) was monitored with an accelerometer (Fig. 10A, top) and by observer rating (Fig. 10 , B and C, middle and bottom). The dose, 0.05 mg/kg, was based on our previous dose-response data that demonstrated improved functioning of advanced parkinsonian monkeys at 0.05 mg/kg quinelorane, without significantly increasing locomotor activity above levels in normal monkeys (Goulet and Madras, 2000) . Monitored by an accelerometer, quinelorane increased overall activity to a greater extent than O-1369 (Fig. 10A , top) and produced higher increases in activity than O-1369 during peak drug response (1-3.5 h). Low-activity animals with advanced parkinsonism (1-4) responded to quinelorane with increased activity ‫,ءءء(‬ p Ͻ 0.001), and animals with higher baseline levels of activity, mild (except 7) did not respond to drug treatment (Fig. 10A, top) . Figure 10 , B and C, presents data from behavioral monitoring of mild (Fig.  10B, middle) or advanced parkinsonian monkeys (Fig. 10C,  bottom) . Quinelorane did not significantly improve any of the behaviors in mild parkinsonian monkeys ( Fig. 10B, middle ; means Ϯ S.E.M.; n ϭ 4). In advanced parkinsonism, quinelorane improved general activity ‫,ء(‬ p Ͻ 0.03), locomotor activity ‫,ء(‬ p Ͻ 0.03), and body freeze ‫,ءء(‬ p Ͻ 0.01), whereas other behaviors (bradykinesia, rigidity, posture, and sedation) did not improve significantly at the dose tested (Fig. 10C , bottom; means Ϯ S.E.M.; n ϭ 4). Onset of effect occurred within 1 h of administration, and effects persisted for several hours (Fig. 11) . The side effect profiles of O-1369 and quinelorane differed. O-1369 promoted oral/facial dyskinesias, whereas quinelorane increased stereotypies (means Ϯ S.E.M.; n ϭ 4) and slightly increased penile erection (data not shown). The grouped values (n ϭ 4) did not differ statistically from baseline values (analysis of variance, Dunnett's postanalysis), but comparisons of individual pre-and postbaseline values differed on a case-by-case basis. Both drugs had no significant effects on social interaction.
DAT Occupancy and Therapeutic Improvement. To determine whether DAT occupancy in living brain correlated with motor improvement, DAT inhibitor occupancy of the DAT in normal brain striatum was monitored by displacement of the DAT probe [
11 C]CFT ). Dif -TABLE 4 DAT occupancy of DAT inhibitors in rhesus monkey striatum: comparison with increased activity produced in parkinsonian monkeys DAT occupancy of DAT inhibitors was monitored by competition between the PET imaging agent and DAT inhibitor ͓ 11 C͔CFT and candidate therapeutic DAT inhibitors. ͓ 11 C͔CFT was injected via the i.v. route in normal rhesus monkeys to acquire baseline DAT levels by PET imaging. Images were acquired over the course of 1 h, followed by i.v. injection of the DAT candidate therapeutic. One hour later, ͓ 11 C͔CFT was injected again, and images were acquired for 60 min, as outlined under Materials and Methods. Results are means Ϯ S.E.M. of three to five independent experiments, with the exception of O-1014. The column designated ЈImproved ActivityЈ indicates whether a DAT inhibitor increased activity at least 40% over baseline levels of activity, computed by calculating activity (measured by an accelerometer) for various times following injection of the test compound compared with baseline activity monitored 3 to 11 days before the drug testing day. Compounds designated ЈNoЈ did not increase activity levels significantly for one or more days after administration. O-1369 O- , O-1163 O- , and O-2099 O- occupied the DAT, but O-1014 O- , O-1231 O- , and O-1973 occupied less than 15% of the DAT at a fixed dose. High-affinity DAT inhibitors with high DAT occupancy also improved activity levels and improved behavioral scores (Tables 2 and 4 ). In contrast, highaffinity DAT inhibitors with little or low DAT occupancy did not increase activity levels. Accordingly, DAT affinity alone did not correlate with DAT occupancy or with enhanced activity in parkinsonian monkeys (Tables 2 and 4 ). To demonstrate that occupancy, as detected by displacement studies corresponded to direct occupancy of a radiolabeled probe, we determined whether a representative DAT inhibitor difluoropine was taken up by the striatum. After conversion of the unlabeled compound to [ 11 C]difluoropine and i.v. administration, [
Compound
11 C]difluoropine accumulated in striatum, as detected by PET imaging (Fig. 12 ) and time-activity curves (n ϭ 2; data not shown).
Discussion
Accumulating evidence suggests that DAT inhibitors may fill a niche in the expanding list of therapeutic strategies to treat Parkinson's disease (Hansard et al., 2002a,b; Nutt et al., 2004 ; but see Frackiewicz et al., 2002; Bara-Jimenez et al., 2004) . Residual dopamine neurons may produce sufficient dopamine to improve parkinsonian signs or alleviate side effects, if augmented by DAT inhibitors (this study); inhibitors of monoamine oxidase B, which metabolize dopamine; or drugs that promote dopamine release (Pahwa et al., 2006) . In the present report, novel DAT inhibitors alleviated selective symptoms of MPTP-induced parkinsonism in cynomolgus monkeys, but they did not induce hyperkinesis or perseverative stereotypies. The convergence of several key parameters was associated with therapeutic potential: high DAT affinity, high DAT occupancy in the striatum, appropriate onset time/duration, minimal side effect profile, and sleep disturbances. High DAT affinity in vitro may be necessary, but it was an inadequate predictor of the therapeutic potential of a DAT inhibitor.
DAT inhibitors alleviated parkinsonian signs, apparently by DAT blockade in residual dopamine neurons. In view of the failure of lead compounds (O-1369, difluoropine) to bind significantly with 32 brain receptors, it is unlikely that other transporters or receptors mediated this positive response. We did not observe the reported blunting effect of NET blockade on DAT inhibitors tested as antiparkinsonian drugs (Hansard et al., 2002a) , because difluoropine, O-1369, and O-2099 displayed high NET affinity (and low SERT affinity). NET blockade, however, may promote sympathomimetic side effects. The inability of O-1369 and other effective DAT inhibitors to reduce bradykinesia, rigidity, or tremor paralleled the effects of the DAT inhibitor brasofensine, which did not bottom, comparison of mild and advanced parkinsonian monkeys responding to O-1369 during peak drug response (1-3.5 h; see (Pearce et al., 2002) . Higher doses may be required to reduce tremor, rigidity, or bradykinesia, as reported clinically for methylphenidate (Halliday and Nathan, 1961) . Alternatively, specific neuronal circuits involved in PD symptoms may be unresponsive to DAT blockade, because they express insufficient DAT or DA. L-dopa, which increases DA levels in excess of endogenous concentrations, improves the full range of motor disabilities in early stages of PD (Mercuri and Bernardi, 2005) . Nonetheless, L-dopa is associated with motor complications, possibly related to its short-half-life and tendency to produce pulsatile DA receptor stimulation (Olanow et al., 2004) . Unlike normal brain, which maintains a relatively stable level of DA, fluctuating plasma L-dopa concentrations probably generate irregular DA levels. Monoamine oxidase B and DAT inhibitors may provide a stable, consistent supply of DA to enhance the therapeutic benefit of L-dopa. L-dopa combined with the DAT inhibitor methylphenidate enhanced the therapeutic outcome of PD patients in one study (Nutt et al., 2004) but not if L-dopa was combined with DAT inhibitors NS 2330 or brasofensine (Frackiewicz et al., 2002; Bara-Jimenez et al., 2004) . In the latter protocol, the long duration of PD (14 Ϯ 5 years), and elderly population (65 Ϯ 12 years) may have precluded a positive outcome. In parkinsonian monkeys, L-dopa synergized with the DAT inhibitor brasofensine (Pearce et al., 2002) but not with BTS 74 398 (Hansard et al., 2004) , even though both DAT inhibitors were effective antiparkinsonian agents alone. Synergy between L-dopa and DAT inhibitors may require a temporal convergence of maximal DAT occupancy by DAT inhibitors combined with L-dopa-induced DA synthesis and release.
Our findings underscore the value of PET imaging to identify candidate therapeutics by detecting DAT occupancy of DAT inhibitors. High DAT occupancy within 1 h of administration, but not high DAT affinity, predicted whether a DAT inhibitor would enhance activity in parkinsonian monkeys. Thus, the high-affinity DAT inhibitors O-2099, O-1163, Fig. 10 . Activity and behavioral monitoring of mild and advanced parkinsonian monkeys (n ϭ 8) before and after treatment with the D 2 -D 3 dopamine receptor agonist quinelorane (0.05 mg/kg). A, top, parkinsonian monkeys with a range of activity levels were monitored continuously by an accelerometer for 5 days, after which quinelorane (0.05 mg/kg i.m.) was administered, and subjects were monitored for five subsequent days. In animals with relatively low levels of activity, quinelorane increased activity ‫,ءءء(‬ p Ͻ 0.001), but it did not do so consistently in higher activity animals. B and C, comparison of response to quinelorane in mild and advanced parkinsonian monkeys during peak drug response (1-3.5 h; see Fig. 11) . B, middle, in mild parkinsonism, quinelorane (0.05 mg/kg i.m.) did not significantly improve any of the behaviors (means Ϯ S.E.M.; n ϭ 4). C, bottom, quinelorane improved behaviors in advanced parkinsonism (means Ϯ S.E.M.; n ϭ 4), including general activity ‫,ء(‬ p Ͻ 0.03), locomotor activity ‫,ء(‬ p Ͻ 0.03), and body freeze ‫,ءء(‬ p Ͻ 0.01), but other behaviors did not improve (bradykinesia, rigidity, posture, and sedation). See Fig. 9 for time course of drug effects. O-1369, and difluoropine occupied DAT in striatum; highaffinity nonamines O-1014 O- , O-1231 O- , and O-1973 O- (Madras et al., 1996 O- , 2003 neither occupied DAT sites in striatum nor promoted increased activity in parkinsonian monkeys. Because certain nonamines may be especially vulnerable to enzymatic hydrolysis in the C-2 position or peripheral lipophilic interactions that prevent brain accumulation, higher doses may be necessary. PET imaging could have predicted the rapid decline of behavioral efficacy of O-1163, if DAT occupancy had been measured 2 to 3 h after O-1163 injection, with 2-h pretreatment time or using a radiotracer of longer duration (e.g., [
18 F]CFT, [ 18 F]altropane, or possibly [ 18 F]O-1369). The failure of brasofensine or NS 2330 to improve PD symptoms (Frackiewicz et al., 2002; Bara-Jimenez et al., 2004) may be related to low DAT occupancy at therapeutic doses or low residual DAT and DA levels.
We were particularly attentive to potential side effects of DAT inhibitors. Potent DAT inhibitors may extend enhanced activity into the nighttime period. Difluoropine, but not O-1369, promoted subject-specific disruptions of sleep patterns at therapeutically relevant doses after early morning exposure. The putative prodrug O-2240 uniquely increased activity during sleep periods, particularly from midnight to 6:00 AM, possibly as a consequence of its slow conversion to O-2099 and persistence in brain regions. Although compromised as a candidate for PD treatment, O-2240 may have therapeutic potential for increasing wakefulness during normal sleep hours, similar to modafinil. Dyskinesias and dystonias are common complications of L-dopa or D 2 -D 3 DA receptor agonists. DAT inhibitors elicited time-dependent but not statistically significant oral/facial dyskinesias, but no other visible side effects (limb dyskinesias or stereotypies). Other DAT inhibitors (GBR 12909, brasofensine, and BTS 74 398) reportedly did not elicit dyskinesias (Hansard et al., 2002a; Pearce et al., 2002) , but the descriptors of dyskinesias in the latter studies (e.g., stereotypy, limb dystonia, chorea, and athetosis) differed from our definitions (Table 1) . In contrast to O-1369, the D 2 -D 3 dopamine receptor agonist quinelorane improved locomotor activity, but it did not improve posture or sedation and increased stereotypic behaviors in some subjects, a side effect profile mirroring that of L-dopa (Hansard et al., 2002a; Pearce et al., 2002) . Abuse liability and reduced appetite are other considerations for potent DAT inhibitors. Although PD patients report blunted responses to the DAT inhibitor methylphenidate (Persico et al., 1998) , this class of compounds presents the potential for diversion. Nonetheless, abuse liability in humans cannot be predicted on the basis of in vitro DAT affinities alone or even self-administration paradigms in animals.
At what stage of PD are DAT inhibitors likely to be effective? DAT binding potential, which correlated inversely with severity of parkinsonism, provided an quantifiable measure of parkinsonian severity, as shown in human PD . Subjects with low DAT binding potentials (80% loss) responded to O-1369, but those with higher DAT binding potential (465 DAT loss) were not as responsive. Impairment was limited in these subjects, and endogenous compensatory mechanisms conceivably masked the effects of DAT inhibitors. In human PD, DAT binding potential reduction of 80% corresponds to a phase between the onset and end stages of PD. We postulate that subjects with DAT reductions 60 to 80% may fall in a suitable therapeutic range for intervention with DAT inhibitors.
DAT blockade conceivably may provide therapeutic benefits in addition to enhancing and stabilizing extracellular DA levels, reducing the threshold and therapeutic doses of Ldopa, and attenuating the L-dopa on-off syndrome. DAT inhibitors may 1) attenuate access of putative exogenous neurotoxins into DA neurons (Uhl 1998; Fleming et al., 2005) ; or 2) attenuate purported neurotoxic effects of L-dopa or of dopamine, by blocking DA sequestration into dopamine neurons. Albeit highly controversial, intracellular accumulation of L-dopa and DA with L-dopa treatment is implicated in accelerating neurodegeneration (for review, see Olanow et al., 2004) . DAT inhibitors may 3) benefit patients in early stages of Parkinson's disease, because DAT blockade abolishes dendritic release of dopamine and resulting self-inhibition, a process that implicates carrier-mediated release of dopamine (Falkenburger et al., 2001) . DAT inhibitors may 4) protect DA neurons by enhancing transport of DA toxins and metabolites into vesicles via the vesicular monoamine transporter-2. DAT inhibitors apparently up-regulate vesicular vesicular monoamine transporter-2 function (Rau et al., 2005) and 5) increase DA diffusion to postsynaptic DA receptors. We postulate that the juxtaposition of the DAT and DA release sites is conceivably misaligned with postsynaptic DA receptors in parkinsonian brains. DAT inhibitors may 6) antagonize the hypotensive or dyskinetic effects of L-dopa, as demonstrated with methylphenidate for hypotension and brasofensine for dyskinesia (Pearce et al., 2002; Nutt et al., 2004) or 7) improve mood, energy, and reduce apathy (Cantello et al., 1989; Chatterjee and Fahn, 2002; Nutt et al., 2004) .
In summary, lead DAT inhibitors that alleviate specific motor deficits of MPTP-induced parkinsonism in monkeys display high DAT occupancy in vivo, low nighttime activity, adequate duration of effect, and few side effects. Pharmacokinetic properties, metabolism, toxicity, tolerance alone or in combination with L-dopa/DA receptor agonists, abuse liability, appetite suppression, and cardiovascular effects will further define their therapeutic potential. Nonetheless, the re- 
